Karine Pavageau

Karine Pavageau

Auto-generated profile, based on publicly available information

Karine Pavageau

Nantes Université, TaRGeT, Translational Research for Gene Therapies, CHU Nantes, INSERM, UMR 1089, Nantes 44000, France

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2025 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
PLPierre-Alban Lalys
Pierre-Alban Lalys
ABAudrey Bourdon
Audrey Bourdon
MBMohammed Bouzelha
Mohammed Bouzelha
DADimitri Alvarez-Dorta
Dimitri Alvarez-Dorta
KPKarine Pavageau
Karine Pavageau
DDDavid Deniaud
David Deniaud

5 February 2026 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
MBMohammed Bouzelha
Mohammed Bouzelha
KPKarine Pavageau
Karine Pavageau
SRSarah Renault
Sarah Renault
EFEnora Ferron
Enora Ferron
NJNicolas Jaulin
Nicolas Jaulin
MMMathieu Mével
Mathieu Mével
In this study, we present an ultrafast, efficient, and broadly applicable strategy for cell membrane modification via tyrosine-selective bioconjugation using diazonium salt derivatives. This chemical approach enables both one-step and two-step functionalization of adherent, suspension, and primary cells with a wide range of ligands, including imaging probes, carbohydrates, biotin, and proteins, without inducing cytotoxicity or immune activation. Cell membrane engineering through bioconjugation has emerged as a powerful tool in biomedical research, given the central role of the membrane in signaling, transport, and cell-cell interactions. In contrast to conventional glyco-engineering methods, which typically require multiday incubations and can induce cellular stress, our approach achieves rapid, precise, and high-density surface functionalization in less than one hour, with improved reproducibility and biological compatibility. We further demonstrate the applicability of this strategy across diverse cell types, including immortalized cell lines and clinically relevant primary cells such as peripheral blood mononuclear cells (PBMCs) and human natural killer (NK) cells. Notably, surface grafting of an EGFR-targeting Nanofitin enhances the cytotoxic activity of NK cells against EGFR-positive cancer cells. In addition, we show that the bioconjugated signal progressively diminishes over successive cell divisions, providing a self-limiting and transient alternative to permanent genetic modifications such as CAR-based engineering, thereby potentially reducing the risk of prolonged immune activation. Finally, the ability to store pre-functionalized cells at -80 °C increases the practicality of this platform for future ready-to-use applications. Overall, this versatile and non-genetic bioconjugation strategy offers a compelling alternative to existing technologies for applications in targeted therapy, diagnostics, and cell-based immunotherapy.

25 July 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
PLPierre-Alban Lalys
Pierre-Alban Lalys
ABAudrey Bourdon
Audrey Bourdon
MBMohammed Bouzelha
Mohammed Bouzelha
DADimitri Alvarez-Dorta
Dimitri Alvarez-Dorta
KPKarine Pavageau
Karine Pavageau
DDDavid Deniaud
David Deniaud
This study investigates novel approaches to improve targeted gene delivery to the liver, a crucial organ for metabolic processes that faces vulnerabilities from various pathologies. Adeno-associated virus (AAV)-based gene therapy has emerged as a promising approach for liver targeting, with numerous investigational avenues. However, administration of high doses of AAV vectors present safety concerns, often requiring the use of corticosteroids and immunosuppression to mitigate immune adverse events. To address this, substantial efforts are underway to engineer optimized capsids to enhance the efficiency and specificity of recombinant AAV (rAAV) targeting hepatocytes, aiming to reduce required dosages. In this study, we employed bioconjugation chemistry to target the Asialoglycoprotein receptor (ASGPR), a C-type lectin abundantly expressed at the surface of hepatocyte membranes. We demonstrated that covalently attaching carbohydrates derived from GalNAc (a known ASGPR ligand) to lysine amino-acids on the rAAV2 capsid significantly enhanced in vivo liver transduction efficiency in mice. These optimized vectors present a promising avenue for the treatment of a spectrum of liver diseases, providing an alternative solution within the framework of liver gene therapy.

16 November 2025 in bioRxiv
Verified
Preprint
Open access
MBMohammed Bouzelha
Mohammed Bouzelha
KPKarine Pavageau
Karine Pavageau
SRSarah Renault
Sarah Renault
EFEnora Ferron
Enora Ferron
NJNicolas Jaulin
Nicolas Jaulin
MMMathieu Mével
Mathieu Mével
In this study, we present an ultrafast, efficient, and broadly applicable strategy for cell membrane modification via tyrosine bioconjugation using diazonium salt derivatives. This chemical approach enables both one-step and two-step functionalization of adherent, suspension, and primary cells with diverse ligands, including imaging probes, carbohydrates, biotin, and proteins, without inducing cytotoxicity or immune activation. Membrane engineering through bioconjugation is emerging as a valuable tool in biomedical research, given the cell membrane’s central role in signaling, transport, and cell-cell interactions. Compared to traditional glyco-engineering methods that often require multiday incubations and can cause cellular stress, our approach achieves precise and high-density grafting in less than one hour, with improved reproducibility and biological compatibility. Importantly, we demonstrate that this strategy can be applied to a variety of cell types, encompassing both immortalized cell lines and primary cells, notably Peripheral Blood Mononuclear Cells (PBMCs) and human effector cells such as natural killer (NK) cells, to enhance their cytotoxic function against EGFR-positive cancer cells via surface-conjugated Nanofitin. Moreover, we show that the bioconjugated signal diminishes over time due to cell division, offering a self-limiting alternative to permanent genetic modifications such as CAR-T, thereby mitigating risks associated with overly prolonged immune activation. Finally, the feasibility of storing pre-functionalized cells at -80 °C expands the practicality of this platform for future ready-to-use applications. Together, these features make our method a compelling alternative to current technologies for applications in targeted therapy, diagnostics, and cell-based immunotherapy.